A Phase 1/2, First-in-human, Open-Label, Dose-Escalation Study of TAK-280, an Investigational B7-H3 X CD3ε Conditional Bispecific Redirected Activation (COBRA) T-cell Engager, in Adult Patients with Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined